This work is licensed under the Creative Commons Attribution 4.0 International License.
Thomas SK. Waldenstrom Macroglobulinemia —- 2021 update on management and future directions. Clin Lymphoma Myeloma Leuk. 2021: S2152-2650(21)02447-2.ThomasSKWaldenstrom Macroglobulinemia —- 2021 update on management and future directions2021S2152-2650(21)02447-2.Search in Google Scholar
Baďurová K, Gregorová J, Vlachová M, Krejčí M, Ševčíková S. Waldenstrom macroglobulinemia. Klin Onkol. 2021;34(6):428–33.BaďurováKGregorováJVlachováMKrejčíMŠevčíkováSWaldenstrom macroglobulinemia20213464283310.48095/ccko202142834911327Search in Google Scholar
Gertz MA. Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2021;96(2):258–69.GertzMAWaldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management20219622586910.1002/ajh.2608233368476Search in Google Scholar
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.McDonaghTAMetraMAdamoMGardnerRSBaumbachABöhmMBurriHButlerJČelutkienėJChioncelOClelandJGFCoatsAJSCrespo-LeiroMGFarmakisDGilardMHeymansSHoesAWJaarsmaTJankowskaEALainscakMLamCSPLyonARMcMurrayJJVMebazaaAMindhamRMunerettoCFrancesco PiepoliMPriceSRosanoGMCRuschitzkaFKathrine SkibelundAESC Scientific Document Group2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure20214236359972610.1093/eurheartj/ehab36834447992Search in Google Scholar
Kwaan HC. Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc. 2013;55(1):75–83.KwaanHCHyperviscosity in plasma cell dyscrasias2013551758310.3233/CH-13169123455837Search in Google Scholar
Consuegra A, PJ Marcos, R Vazquez, Pombo J, Deben G, Verea-Hernando H. Diffuse interstitial lung disease as a first manifestation of Waldenström macroglobulinemia: case report and review of the literature. Arch Bronconeumol. 2014;50(4):151–3.ConsuegraAMarcosPJVazquezRPomboJDebenGVerea-HernandoHDiffuse interstitial lung disease as a first manifestation of Waldenström macroglobulinemia: case report and review of the literature2014504151310.1016/j.arbres.2013.05.00924629759Search in Google Scholar
Green AP, Gonzalez AC, Alperin JB, Burner JD, Yates SG. The utility of therapeutic plasma exchange in hyperviscosity syndrome associated with juvenile rheumatoid arthritis: A case report. J Clin Apher. 2021;36(4):658–63.GreenAPGonzalezACAlperinJBBurnerJDYatesSGThe utility of therapeutic plasma exchange in hyperviscosity syndrome associated with juvenile rheumatoid arthritis: A case report20213646586310.1002/jca.2190333945169Search in Google Scholar
Hernández-Molina G, Bermúdez-Bermejo P. Hyperviscosity in primary Sjogren's syndrome: clinical implications. Int J Rheum Dis. 2017;20(1):84–9.Hernández-MolinaGBermúdez-BermejoPHyperviscosity in primary Sjogren's syndrome: clinical implications201720184910.1111/1756-185X.1275126807556Search in Google Scholar
Schatz MJ, Wilkins CS, Otero-Marquez O, Chui TYP, Rosen RB, Gupta M. Multimodal imaging of Waldenstrom macroglobulinemia-associated hyperviscosity-related retinopathy treated with plasmapheresis. Case Rep Ophthalmol Med. 2021;2021:6816195.SchatzMJWilkinsCSOtero-MarquezOChuiTYPRosenRBGuptaMMultimodal imaging of Waldenstrom macroglobulinemia-associated hyperviscosity-related retinopathy treated with plasmapheresis20212021681619510.1155/2021/6816195869500434956683Search in Google Scholar
Kikukawa Y, Yamamura-Fujimoto A, Endo S, Miyagawa E, Kawano Y, Ueno S, Mitsuya H, Hata H, Okuno Y. Successful treatment of Bing-Neel syndrome accompanying Waldenstrom's macroglobulinemia with R-MPV: a case report. J Clin Exp Hematop. 2015;55(2):113–9.KikukawaYYamamura-FujimotoAEndoSMiyagawaEKawanoYUenoSMitsuyaHHataHOkunoYSuccessful treatment of Bing-Neel syndrome accompanying Waldenstrom's macroglobulinemia with R-MPV: a case report2015552113910.3960/jslrt.55.11326490525Search in Google Scholar
Kudo N, Usui M, Nakabo Y, Yoshida KI, Miki K, Osafune T, Nishimura K, Imashuku S. Waldenstrom's macroglobulinemia: a report of two cases, one with severe retinopathy and one with renal failure. Case Rep Hematol. 2017;2017:3732902.KudoNUsuiMNakaboYYoshidaKIMikiKOsafuneTNishimuraKImashukuSWaldenstrom's macroglobulinemia: a report of two cases, one with severe retinopathy and one with renal failure20172017373290210.1155/2017/3732902568459529225979Search in Google Scholar
Mihalcea DJ, Florescu M, Vinereanu D. Mechanisms and genetic susceptibility of chemotherapy-induced cardiotoxicity in patients with breast cancer. Am J Ther. 2017;24(1):e3–e11.MihalceaDJFlorescuMVinereanuDMechanisms and genetic susceptibility of chemotherapy-induced cardiotoxicity in patients with breast cancer2017241e3e1110.1097/MJT.000000000000045327145188Search in Google Scholar
Mihalcea D, Florescu M, Bruja R, Patrascu N, Vladareanu AM, Vinereanu D. 3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin's lymphoma. Sci Rep. 2020;10(1):18473.MihalceaDFlorescuMBrujaRPatrascuNVladareanuAMVinereanuD3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin's lymphoma20201011847310.1038/s41598-020-75043-3759519533116212Search in Google Scholar
Florescu M, Magda LS, Enescu OA, Jinga D, Vinereanu D. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr. 2014;27(1):83–92.FlorescuMMagdaLSEnescuOAJingaDVinereanuDEarly detection of epirubicin-induced cardiotoxicity in patients with breast cancer2014271839210.1016/j.echo.2013.10.00824268372Search in Google Scholar
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801.ZamoranoJLLancellottiPRodriguez MuñozDAboyansVAsteggianoRGalderisiMHabibGLenihanDJLipGYHLyonARLopez FernandezTMohtyDPiepoliMFTamargoJTorbickiASuterTMESC Scientific Document Group2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)201637362768280110.1093/eurheartj/ehw21127567406Search in Google Scholar
Pancheri E, Guglielmi V, Wilczynski GM, Malatesta M, Tonin P, Tomelleri G, Nowis D, Vattemi G. Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects. Cancers (Basel). 2020;12(9):2540.PancheriEGuglielmiVWilczynskiGMMalatestaMToninPTomelleriGNowisDVattemiGNon-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects2020129254010.3390/cancers12092540756397732906684Search in Google Scholar
Atalay F, Gulmez O, Ozsancak Ugurlu A. Cardiotoxicity following cyclophosphamide therapy: a case report. J Med Case Rep. 2014;8:252.AtalayFGulmezOOzsancak UgurluACardiotoxicity following cyclophosphamide therapy: a case report2014825210.1186/1752-1947-8-252410621325023062Search in Google Scholar
Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K, Morioka S, Furukawa Y. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009;54(2):330–4.KatayamaMImaiYHashimotoHKurataMNagaiKTamitaKMoriokaSFurukawaYFulminant fatal cardiotoxicity following cyclophosphamide therapy2009542330410.1016/j.jjcc.2009.01.00619782276Search in Google Scholar
de Salvi Guimarães F, de Moraes WM, Bozi LH, Souza PR, Antonio EL, Bocalini DS, Tucci PJ, Ribeiro DA, Brum PC, Medeiros A. Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation. Mol Cell Biochem. 2017;424(1–2):87–98.de Salvi GuimarãesFde MoraesWMBoziLHSouzaPRAntonioELBocaliniDSTucciPJRibeiroDABrumPCMedeirosADexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation20174241–2879810.1007/s11010-016-2846-327761848Search in Google Scholar
Ng KH, Dearden C, Gruber P. Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears? BMJ Case Rep. 2015;2015:bcr2014208203.NgKHDeardenCGruberPRituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?20152015bcr2014208203.10.1136/bcr-2014-208203436903625733089Search in Google Scholar
Lazarevic VLj, Liljeholm M, Forsberg K, Söderberg S, Wahlin A. Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49(6):1209–11.LazarevicVLjLiljeholmMForsbergKSöderbergSWahlinAFludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia200849612091110.1080/1042819080200771818452089Search in Google Scholar
Montrone D, Correale M, Franzese MG, Ieva R, Di Biase M, Capalbo SF. Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab. J Cardiovasc Med (Hagerstown). 2015;16 Suppl 1:S65.MontroneDCorrealeMFranzeseMGIevaRDi BiaseMCapalboSFPulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab201516Suppl 1S6510.2459/JCM.0b013e3283621adf25643063Search in Google Scholar